Aflibercept
Brand name: Eylea
Rank #356 of 500 drugs by total cost
$28.0M
Total Cost
10,899
Total Claims
$28.0M
Total Cost
105
Prescribers
$2,567
Cost per Claim
2,493
Beneficiaries
11,546
30-Day Fills
$266K
Avg Cost/Provider
104
Avg Claims/Provider
About Aflibercept
Aflibercept (sold as Eylea) was prescribed 10,899 times by 105 Medicare Part D providers in 2023, costing the program $28.0M. At $2,567 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 353 | Olanzapine/Samidorphan Malate (Lybalvi) | $28.3M | 18,294 |
| 354 | Interferon Beta-1b (Betaseron) | $28.3M | 2,983 |
| 355 | Iloperidone (Fanapt) | $28.2M | 13,925 |
| 356 | Aflibercept (Eylea) | $28.0M | 10,899 |
| 357 | Fostemsavir Tromethamine (Rukobia) | $27.8M | 3,094 |
| 358 | Colchicine (Colchicine) | $27.5M | 314,046 |
| 359 | Valsartan/Hydrochlorothiazide (Valsartan-Hydrochlorothiazide) | $27.5M | 510,583 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology